Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Merck Sharp & Dohme Ltd
Femme et Homme Max 99 ans
Merck Sharp & Dohme Ltd. (MSD) (UK)
MAJ Il y a 4 ans
Does montelukast affect the structural proteins in the sputum of patients with asthma?
Not provided at time of registration
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Ltd
MAJ Il y a 4 ans
A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK-0822 in Patients with Osteoarthritis
1) To evaluate the efficacy of MK-0822 5 mg once daily relative to placebo in the prevention of knee cartilage loss over 12 months of treatment based on MRI assessments of cartilage normalized volume ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Ltd. (MSD) (UK)
MAJ Il y a 4 ans
A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI
Not provided at time of registration
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Ltd
MAJ Il y a 4 ans
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia
In patients with sitosterolemia who have been taking ezetimibe 10 mg daily for at least 6 months prior to entry, to compare the effects of adding ezetimibe 30 mg versus placebo to ongoing ezetimibe 10...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Ltd
MAJ Il y a 4 ans
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study to Assess the Efficacy and Safety of MK-0952 in Patients With Alzheimer’s Disease
To evaluate the efficacy of MK-0952 37.5 mg daily over a 4-week treatment period in improving cognitive function in patients with mild-to-moderate AD as assessed by the 0-hour to 24-hour difference in...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Ltd. (MSD) (UK)
MAJ Il y a 4 ans
Erbitux in preoperative chemo-radiotherapy followed by excisional surgery
http://cancerhelp.cancerresearchuk.org/trials/a-study-looking-giving-biological-therapy-as-well-as-combined-chemotherapy-and-radiotherapy-before-surgery-cancer-back-passage-xerxes
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations